180 related articles for article (PubMed ID: 25667625)
21. [A single-center, randomized controlled trial of PEG-rhG-CSF and common rhG-CSF to promote neutrophil recovery after induction chemotherapy in newly diagnosed acute myeloid leukemia].
Liu KQ; Wang Y; Zhao Z; Lin D; Zhou CL; Liu BC; Gong XY; Zhao XL; Wei SN; Zhang GJ; Gong BF; Li Y; Liu YT; Mi YC; Wang JX; Wei H
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):497-501. PubMed ID: 31340623
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia.
Liu XT; Zhao YX; Jia GW; Yang F; Zhang CZ; Han B; Dai JH; Han YQ; Tang BH; Yang XM; Shi HY; Zhou Y; Sui ZG; Chen JZ; van den Anker JN; Zhao W
Br J Clin Pharmacol; 2021 Aug; 87(8):3292-3300. PubMed ID: 33506975
[TBL] [Abstract][Full Text] [Related]
23. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
Huang HQ; Bai B; Gao YH; Zou DH; Zou SH; Tan H; Song YP; Li ZY; Jin J; Li W; Su H; Gong YP; Zhong MZ; Shuang YR; Zhu J; Zhang JQ; Cai Z; Teng QL; Sun WJ; Yang Y; Xia ZJ; Chen HL; Hua LM; Bao YY; Wu N
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):825-830. PubMed ID: 29166732
[No Abstract] [Full Text] [Related]
24. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
Liu C; Hao Y; Wang L; Meng F; Wen F; Zhong D
Thorac Cancer; 2021 Apr; 12(8):1154-1161. PubMed ID: 33590721
[TBL] [Abstract][Full Text] [Related]
25. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
26. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
Zhang JY; Liu YX; Wang H; Mi L; Song GH; Jiang HF; Yan Y; Shao B; Kong WY; Zhang RY; Ran R; Liu XR; Wang J; Lin YT; Li HP
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2718-2721. PubMed ID: 30220167
[No Abstract] [Full Text] [Related]
27. A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.
Huang J; Lu S; Wang J; Jiang L; Luo X; He X; Wu Y; Wang Y; Zhu X; Chen J; Tang Y; Chen K; Tian X; Shi B; Guo L; Zhu J; Sun F; Zhen Z; Zhang Y
Cancer Med; 2023 Jul; 12(13):14130-14137. PubMed ID: 37183837
[TBL] [Abstract][Full Text] [Related]
28. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
Sun XS; Wang Z; Ren SH; Zhang HL; Liu LJ; Du HB; Liu XW; Liu JF
Thorac Cancer; 2022 Sep; 13(17):2429-2435. PubMed ID: 35859328
[TBL] [Abstract][Full Text] [Related]
29. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
Kocherlakota P; La Gamma EF
Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human granulocyte colony-stimulating factor in preterm neonates with sepsis and relative neutropenia: a randomized, single-blind, non-placebo-controlled trial.
Gathwala G; Walia M; Bala H; Singh S
J Trop Pediatr; 2012 Feb; 58(1):12-8. PubMed ID: 21296862
[TBL] [Abstract][Full Text] [Related]
31. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy.
Liu F; Du Y; Cai B; Yan M; Yang W; Wang Q
J Cancer Res Ther; 2017; 13(5):790-795. PubMed ID: 29237905
[TBL] [Abstract][Full Text] [Related]
32. Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor.
Chen C; Qi J; Wang J
J Oncol Pharm Pract; 2023 Apr; 29(3):727-730. PubMed ID: 35833225
[TBL] [Abstract][Full Text] [Related]
33. Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia.
Bernini JC; Wooley R; Buchanan GR
J Pediatr; 1996 Oct; 129(4):551-8. PubMed ID: 8859262
[TBL] [Abstract][Full Text] [Related]
34. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.
Yang S; Chen SS; Zhang CG; Zhou YL; Xiu M; Zhang P
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38925586
[TBL] [Abstract][Full Text] [Related]
35. Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy.
Kabaya K; Obuchi M; Watanabe M; Kusaka M; Seki M
Oncol Res; 1995; 7(3-4):165-71. PubMed ID: 8555650
[TBL] [Abstract][Full Text] [Related]
36. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor.
Hellmich B; Schnabel A; Gross WL
Semin Arthritis Rheum; 1999 Oct; 29(2):82-99. PubMed ID: 10553980
[TBL] [Abstract][Full Text] [Related]
37. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
Shi YK; Feng FY; Sun Y
Zhonghua Nei Ke Za Zhi; 1994 Nov; 33(11):739-42. PubMed ID: 7541325
[TBL] [Abstract][Full Text] [Related]
38. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; Jiang AM; Chen SS; Yang SE; Wang SS; Wang JH; Pan YY; Ren BY; Chen YJ; Ouyang LZ; Lei KJ; Gao JH; Huang WH; Huang Z; Shou T; He YL; Cheng J; Sun Y; Li WM; Cui SD; Wang X; Rao ZG; Ma H; Liu W; Wu XY; Shen WX; Cao FL; Xiao ZM; Wu B; Tian SY; Meng D; Shen P; Wang BY; Wang Z; Zhang J; Wang L; Hu XC
Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
[TBL] [Abstract][Full Text] [Related]
39. Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy.
Hansen PB; Johnsen HE; Ralfkiaer E; Hansen NE
Br J Haematol; 1993 Aug; 84(4):581-5. PubMed ID: 7692936
[TBL] [Abstract][Full Text] [Related]
40. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia.
Kocherlakota P; La Gamma EF
Pediatrics; 1998 Nov; 102(5):1107-11. PubMed ID: 9794941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
